Avid Radiopharmaceuticals
Carey Horchler has extensive work experience in the field of chemistry and research. Carey began their career as a Postdoctoral Fellow at Research Triangle Institute in 1996. In 1997, they joined AstraZeneca R&D as a Scientist, where they developed their expertise in synthetic organic chemistry and team collaboration for 13 years. During their time at AstraZeneca, they also gained knowledge in medicinal chemistry applications, experimental design techniques, and lean six sigma process improvement methodology. In 2010, Carey joined Avid Radiopharmaceuticals, where they have held various positions including Senior Research Chemist, Associate Director of Chemistry, Director of Chemistry for Imaging R&D, and currently, as the Executive Director of Imaging R&D Chemistry. Carey'swork at Avid Radiopharmaceuticals focuses on research and development in the field of imaging chemistry.
Carey Horchler obtained a Doctor of Philosophy (Ph.D.) degree in Organic Chemistry from Texas A&M University, where they studied from 1990 to 1995. Additionally, Carey attended Trinity University, although no specific degree or field of study information was provided for this institution.
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.